HER2-positive Breast Cancer clinical trials

T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer

This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.

HER3-DXd for Advanced Breast Cancer After T-DXd

This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.

Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer

This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.

GQ1001 plus pyrotinib for HER2-positive metastatic breast cancer

This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.

Trastuzumab-rezetecan for breast cancer with HER2 protein

This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.

New drug for HER2-positive advanced breast cancer

This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.

Testing new drug combos for HER2-positive breast cancer not responding to first therapy

This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.

Comparing two treatments for HER2-positive breast cancer

This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.

HER2-Positive Breast Cancer Treatment Patterns Study

This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.

HER2+ CNS Surveillance

Oral paclitaxel for HER2-positive breast cancer before surgery

This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.

Culmerciclib for HR+ HER2+ advanced breast cancer

This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.

New PET scan to predict breast cancer treatment response

This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.

Testing a new combination treatment for advanced breast cancer

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.

Test drug combo for metastatic breast cancer with AR-positive type

This Phase 1 trial tests palbociclib (a pill) plus avelumab (an IV antibody) for people with metastatic or hard-to-remove locally advanced breast cancer that is AR-positive but otherwise triple-negative. The goal is to see if the treatment is safe and potentially effective for this specific cancer subtype.

Entinostat plus pyrotinib and hormone therapy for advanced breast cancer

This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.

Zanidatamab plus chemo before surgery for HER2+ breast cancer

This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.

Pembrolizumab plus low-dose oral chemo for chest wall breast cancer

This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.

Brain MRI screening during chemotherapy for breast cancer

This trial checks the brain using MRI in people with breast cancer that has spread outside the breast or can’t be fully removed. The goal is to screen for brain involvement and see how MRI findings fit with treatment timing, when it’s safe to do so.

Study drug for TP53 Y220C-mutated advanced cancers

This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.

Local treatment for ER/PR-positive limited spread breast cancer

This Phase 2 study tests whether treating a small number of metastatic spots with a local approach (like targeted radiation, surgery, or ablation) can help people with ER/PR-positive breast cancer. It aims to help when the cancer has spread only to a few areas and has not significantly worsened after initial whole-body treatment.

Testing drug combinations for recurrent or advanced ER-positive breast cancer

This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.

Pre-surgery neratinib plus hormone therapy with trastuzumab

This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.

Study compares two HER2 breast cancer treatments after surgery

This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.